Zydus Lifesciences (Erstwhile: Cadila healthcare)

Few major developments today (CNBC interview)

  • Received emergency use approval from DCGI for use of Pegylated Interferon alpha-2b, ‘Virafin’ in treating moderate COVID-19 infection in adults
  • Current vaccine capacity is 1-1.2 cr. doses/month. Looking to double the capacity in next 3-4 months
  • Final endpoint data should come by May after which they will apply for emergency use authorization
  • Can repurpose vaccine for South African and other variants

Update: Useful management interview with ET about their drug approval

https://www.youtube.com/watch?v=p66G8aHG-d4

Disclosure: Invested (position size here)

1 Like